Recent News

• 09.17.2025 - Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
• 09.02.2025 - Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
• 08.27.2025 - Rezolute to Participate in Upcoming Investor Conferences
• 08.20.2025 - Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
• 07.22.2025 - Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Recent Filings

• 09.17.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 09.17.2025 - 8-K Current report
• 09.17.2025 - EX-99.1 EX-99.1
• 09.02.2025 - 8-K Current report
• 09.02.2025 - EX-99.1 EX-99.1
• 08.27.2025 - 3 Initial statement of beneficial ownership of securities
• 08.27.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.20.2025 - EX-99.1 EX-99.1
• 08.20.2025 - 8-K Current report
• 08.08.2025 - EFFECT Notice of Effectiveness